Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide

References

• BleeckerERSilerTOwenRKramerBBronchodilator efficacy and safety of indacaterol 150 µg once daily in patients with COPD: an analysis of pooled dataInt J Chron Obstruct Pulmon Dis2011643143822003288
   PubMed Web of Science ®Google Scholar
• KerwinEMWilliamsJIndacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspectiveTher Adv Respir Dis201371253723296242
   PubMed Web of Science ®Google Scholar
• RidoloEMontagniMOlivieriERiario-SforzaGGIncorvaiaCRole of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a reviewInt J Chron Obstruct Pulmon Dis2013842543224082783
   PubMed Web of Science ®Google Scholar
• MetaxasEIBalisEThe safety of indacaterol for the treatment of COPDExpert Opin Drug Saf201817663764229741108
   PubMed Web of Science ®Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772974123118536
   PubMed Web of Science ®Google Scholar
• CarterNJInhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary diseaseDrugs201373774175323677802
   PubMed Web of Science ®Google Scholar
• MolimardMD’AndreaPOnce-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profileExpert Rev Clin Pharmacol20136550351723971870
   PubMed Web of Science ®Google Scholar
• Riario-SforzaGGRidoloERiario-SforzaEIncorvaiaCGlycopyrronium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Rev Respir Med201591233325547422
   PubMed Web of Science ®Google Scholar
• SchachterENIndacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPDDrugs Today201349743744623914352
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCazzolaMQVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary diseaseExpert Opinion on Pharmacotherapy20151671079109025843089
   PubMed Web of Science ®Google Scholar
• RidoloEMontagniMRiario-SforzaGGBaroniMIncorvaiaCCombination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safetyTher Adv Respir Dis201592495525691493
   PubMed Web of Science ®Google Scholar
• FickerJHRabeKFWelteTRole of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrroniumPulm Pharmacol Ther201745193328389258
   PubMed Web of Science ®Google Scholar
• HanJDaiLZhongNIndacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trialsBMC Pulm Med2013251326
   Web of Science ®Google Scholar
• ChungVCHMaPHXHuiDSCTamWWSTangJLIndacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysisPLoS One201388e7078423967106
   PubMed Web of Science ®Google Scholar
• GeakeJBDabscheckEJWood-BakerRIndacaterolCCJA once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20151CD01013925575340
   PubMedGoogle Scholar
• IsmailaASHuismanELPunekarYSKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2015102495251726604738
   PubMed Web of Science ®Google Scholar
• RosselliDKarpfEOlayaASystematic review and meta-analysis of the effectiveness and safety of combination therapy with Glycopirronium-Indacaterol compared with other first line therapies in patients with chronic obstructive pulmonary diseaseValue Health2015187A494
   Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2018 Available from: http://goldcopd.org/glogal-strategy-management-prevention.copd-2018Accessed October 13, 2018
   Google Scholar
• PriceDBØstremAThomasMWelteTDual bronchodilation in COPD: lung function and patient-reported outcomes – a reviewInt J Chron Obstruct Pulmon Dis20161214116828115839
   PubMed Web of Science ®Google Scholar
• DonohueJFJonesPWBartelsCCorrelations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther201849111929277690
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• KardosPHagedorn-PeinzIThe impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study – the FAVOR studyInt J Chron Obstruct Pulmon Dis201813697729317812
   PubMed Web of Science ®Google Scholar
• TsiligianniIMezziKFucileSResponse to Indacaterol/Glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE programCOPD201714437538128594587
   PubMedGoogle Scholar
• AnzuetoARKostikasKMezziKIndacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME studyRespir Res201819112129925383
   PubMed Web of Science ®Google Scholar
• PłusaTPhysicians From Medical Centers In Poland GOEvaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland – observational study (OSQO)Pol Merkur Lekarski20174325615816229084188
   PubMedGoogle Scholar
• KocksJWHSeysSFvan DuinTSDiamantZTsiligianniIGAssessing patient-reported outcomes in asthma and COPD patients: which can be recommended in clinical practice?Curr Opin Pulm Med2018241182329084018
   PubMed Web of Science ®Google Scholar
• PriceDLeeAJSimsEJCharacteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort studyPrimary Care Respiratory Journal2013222161168
   Google Scholar
• AppletonSJonesTPoolePIpratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20062CD001387
   Google Scholar
• MolimardMRaherisonCLignotSChronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patientsEur Respir J2017492160179428182569
   PubMed Web of Science ®Google Scholar
• van der PalenJThomasMChrystynHA randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devicesNPJ Prim Care Respir Med20162611607927883002
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDLViswanadBGasserMWaldaSGutzwillerFSFactors associated with appropriate inhaler use in patients with COPD – lessons from the REAL surveyInt J Chron Obstruct Pulmon Dis20181369570229520137
   PubMed Web of Science ®Google Scholar
• ManKNTianZLamDCWanJMFTan-UnKCSatisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operationInt J Chron Obstruct Pulmon Dis2018131949196329942127
   PubMed Web of Science ®Google Scholar
• AltmanPBergnaMAGarciaGRGuerinTPinoAVWhitefordJLPatient perception of Breezhaler® and Ellipta® device feedback mechanisms in COPD: The ADVANTAGE StudyCurr Med Res Opin20185017
   Google Scholar
• AltmanPWehbeLDederichsJComparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trialBMC Pulm Med201818110029898702
   PubMed Web of Science ®Google Scholar